Skip to main navigation Skip to search Skip to main content

Erratum: Osimertinib for patients with non–small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09) (Journal of Clinical Oncology (2020) DOI: 10.1200/JCO.19.00931)

  • Jang Ho Cho
  • , Sung Hee Lim
  • , Ho Jung An
  • , Ki Hwan Kim
  • , Keon Uk Park
  • , Eun Joo Kang
  • , Yoon Hee Choi
  • , Mi Sun Ahn
  • , Myung Hee Lee
  • , Jong Mu Sun
  • , Se Hoon Lee
  • , Jin Seok Ahn
  • , Keunchil Park
  • , Myung Ju Ahn

Research output: Contribution to journalComment/debatepeer-review

Abstract

The February 10, 2020, article by Cho et al, entitled “Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)” (J Clin Oncol 10.1200/JCO.19.00931), was published with an error.

Original languageEnglish
Pages (from-to)1248
Number of pages1
JournalJournal of Clinical Oncology
Volume38
Issue number11
DOIs
Publication statusPublished - 2020 Apr 10
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2020 American Society of Clinical Oncology. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Erratum: Osimertinib for patients with non–small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09) (Journal of Clinical Oncology (2020) DOI: 10.1200/JCO.19.00931)'. Together they form a unique fingerprint.

Cite this